Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02185053Phase 2Completed

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

Role: lead

NCT02549196Phase 2Completed

A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type

Role: lead

NCT02434666Phase 2Completed

Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07

Role: lead

NCT02860065Phase 2Withdrawn

CPC-201 Alzheimer's Disease Type Dementia: PET Study

Role: lead

All 4 trials loaded